These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16763827)

  • 21. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
    Savic RM; Barrail-Tran A; Duval X; Nembot G; Panhard X; Descamps D; Verstuyft C; Vrijens B; Taburet AM; Goujard C; Mentré F;
    Clin Pharmacol Ther; 2012 Nov; 92(5):575-83. PubMed ID: 23033116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
    Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
    Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
    HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
    HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
    King JR; Yogev R; Jean-Philippe P; Graham B; Wiznia A; Britto P; Carey V; Hazra R; Acosta EP;
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4290-4. PubMed ID: 21670182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
    J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir.
    Fournier C; Higgins N; Thomas R; Baril JG; Thibeault D; Lalonde R; Sheehan NL
    Ther Drug Monit; 2013 Apr; 35(2):264-9. PubMed ID: 23503454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
    Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
    AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
    Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM
    HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
    Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
    J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
    Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
    Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
    Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD
    Clin Pharmacokinet; 2012 Dec; 51(12):809-22. PubMed ID: 23044523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.